MYD88 and diffuse large B-cell lymphoma: For example, somatically acquired mutations or deletions in genes involved in B-cell receptor (BCR) signaling (CD79,12CARD11,13BLIMP14, 15), apoptosis (PIM1,16TNFAIP3,17TRAF5(ref. 18)) or inflammatory responses (MYD88(ref. 19)) have recently been shown to contribute to DLBCL pathogenesis.